ChemoCentryx Soars On Phase III Avacopan Data In ANCA Vasculitis
The company and partner Vifor said the selective complement 5a receptor inhibitor met both primary and multiple secondary endpoints; US and EU filings are planned for 2020.
You may also be interested in...
Prompted by a presidential executive order on advancing kidney health, the US Medicare agency has proposed five new end-stage renal disease (ESRD) payment models to encourage greater use of home dialysis and kidney transplants to Medicare and Medicaid beneficiaries.
Switzerland’s leader in iron deficiency therapies wants to add new products in this and adjacent therapeutic areas, as strong revenue growth in 2018 backs its strategy of concentrating its efforts on the pharmaceuticals business.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.